Study on her2-positive early-stage breast cancer treatment
Part of Cancer clinical trials.
This study looks at how well a new test can help manage her2-positive early-stage breast cancer. It includes patients who have had treatment before or after surgery with trastuzumab and possibly pertuzumab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have early-stage breast cancer (stage I to III) that can be removed with surgery.
- Your tumor is her2-positive, meaning it has a specific protein that helps it grow.
- You received treatment with trastuzumab (and possibly pertuzumab) before or after surgery.
- You have been seen by your doctor for at least 3 years after your surgery.
- You have not been diagnosed with any other invasive cancer before this breast cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at different types of HER2-positive breast cancer to learn more about the disease. It is for people with early-stage or locally advanced breast cancer who have not yet received treatment, and aims to help doctors find better ways to personalize care.
This study follows patients with HER2-positive breast cancer who received chemotherapy and a targeted drug (trastuzumab) before surgery but did not have a complete response. Researchers want to understand which follow-up treatments work best to prevent cancer from coming back.
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This study tests whether using PET scans (a special imaging technique) to monitor how your HER2-positive breast cancer responds to treatment before surgery can help doctors choose the best treatment plan for you. The goal is to improve outcomes by personalizing therapy based on how your tumor responds.
This trial tests whether giving trastuzumab before surgery can improve outcomes for people with HER2-positive early breast cancer. Trastuzumab is a targeted medicine that helps treat HER2-driven cancer before the tumor is removed.
Hear when a new Breast Cancer Early Stage Breast Cancer (Stage 1-3) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.